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Abstract
Background
Congenital toxoplasmosis (CT) causes a substantial disease burden worldwide. The aim of
this study was to estimate the disease burden of CT in Denmark, a developed country with
free public healthcare and nationwide data available.
Methods
Using data primarily from two public health surveillance programmes conducted between
1992 and 2007, we estimated the incidence, occurrence of sequelae, mortality and the
burden of disease in terms of disability-adjusted life years (DALYs) of CT in Denmark in
2014.
Findings
We estimated that 14 children were born with CT in 2014, of which six will have developed
sequelae by the age of 12. CT resulted in a total disease burden of 123 DALYs (95% uncer-
tainty interval [UI], 100–148), of which 78 (95% UI, 64–94) were due to foetal loss and 2
(95% UI, 1–3) were due to neonatal death; the remaining burden was due to moderate to
severe life-long sequelae. A comparison of the estimated incidence of CT with the number
of reported CT cases in 2008–2014 indicated that for each reported CT case, at least five
other CT cases could be expected to have occurred and gone unreported.
Interpretation
Early onset, severity, and life-long duration of sequelae have a major effect on the disease
burden of CT. Our data suggest that CT is under-diagnosed or under-reported in Denmark.
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The estimated disease burden and public health impact in Denmark is lower than in other
European countries, highlighting the need for country-specific studies.
Introduction
Toxoplasmosis is a zoonotic disease. Humans can acquire Toxoplasma gondii infection
through foodborne or environmental exposure. Recent estimates suggest that more than one
million cases of foodborne toxoplasmosis occur in Europe annually [1]. Infection of pregnant
women by T. gondii is particularly problematic, as the parasite may cross the placenta and
infect the unborn child, resulting in congenital toxoplasmosis (CT) [2]. CT may lead to miscar-
riage, stillbirth or sequelae in the child; however, the majority of congenitally infected children
appear asymptomatic at birth. The maternal-foetal transmission rate upon primary infection
increases with gestational age, ranging from 6% (95% confidence interval [CI], 3–9) at 13
weeks of gestation to 72% (95% CI, 60–81) at 36 weeks of gestation [2]. The earlier the foetus is
infected, the higher the risk of developing severe sequelae [2]. The typical clinical signs of CT
include chorioretinitis, intracranial calcification, hydrocephalus and CNS abnormalities lead-
ing to neurological deficiencies (psychomotor or other neurological deficiencies, convulsions,
and mental retardation). Furthermore, CT may cause foetal loss and neonatal death [3]. In
contrast, acquired T. gondii infection will in most cases run a subclinical course or cause
minor symptoms (fever, fatigue, lymphadenopathy); nevertheless, some individuals may
develop ocular or generalized toxoplasmosis [4].
Burden of disease studies have been recognized as a powerful tool to enable policy makers
and other stakeholders to set appropriate, evidence-based priorities for food safety interven-
tions [5]. A recent World Health Organization (WHO) initiative to estimate the regional and
global burden of foodborne diseases (Foodborne Disease Burden Epidemiology Reference
Group, FERG) calculated combined disease burden estimates for congenital and acquired
toxoplasmosis in Europe, ranking T. gondii the third most important cause of foodborne dis-
ease [1]. WHO—FERG highlighted the need for national studies to achieve more accurate and
country-specific estimates. However, only a few countries have so far been able to accomplish
this task. In The Netherlands, the disease burden caused by toxoplasmosis ranked highest
among 14 foodborne diseases and fifth among 32 infectious diseases [6,7], largely explained by
the burden of CT. In Greece, toxoplasmosis ranked fifth among 19 foodborne diseases [8]. In
the United States, toxoplasmosis ranked second among seven leading foodborne pathogens
mainly due to the burden of acquired toxoplasmosis [9]. The burden of CT has also been esti-
mated in low-income countries such as Nepal [10] and Kyrgyzstan [11]. All these studies iden-
tified substantial data gaps due to the lack of effective surveillance of the disease at the national
level.
In this study, we estimated the disease burden of CT in 2014 in Denmark—a developed
country with a free public healthcare system, a history of active CT-screening of newborns,
and nationwide data available. In Denmark, one regional study and one national study on CT
have been conducted [12,13]. We estimated the national incidence, occurrence of sequelae,
mortality, and the burden of CT in terms of disability-adjusted life years (DALYs), a metric
that enables an objective and complete comparison between diseases and risk factors [14,15].
Furthermore, we compared the estimated incidence of CT in Denmark with the number of CT
cases captured by surveillance during a period with no active screening to assess the current
level of under-reporting of the disease.
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Materials and methods
DALYs reflect the sum of the number of years lived with disability (YLDs) and the number of
years of life lost (YLLs) due to premature mortality. YLDs are estimated by multiplying the
number of incident cases with the duration and the disability weight (DW) of a health state,
while YLLs are estimated by multiplying the number of deaths and life expectancy at the age of
death [16]. DWs express the proportional reduction of quality of life due to sequelae on a scale
from 0 to 1, where 0 means perfect health and 1 equals death [17], and were obtained from the
Global Burden of Disease 2013 study [15] and Havelaar et al (2007) [18]. We calculated
DALYs for 2014, and used the Danish life expectancy table [19] to estimate YLDs and the fron-
tier national life expectancy projected for the year 2050 by the World Population Prospects
2012 (UN Population Division, 2013) [20] to estimate YLLs.
Health outcomes
CT comprises a variety of health outcomes that occur after congenital infection with T. gondii
(Fig 1). In this paper, we use the expression CT also for children with no apparent symptoms
or signs at birth due to the congenital T. gondii infection so as to include all possible outcomes
in the disease burden estimate. Health outcomes of CT were defined according to Havelaar
et al. (2007) [18]: including foetal loss, sequelae manifesting in the first year of life (chorioreti-
nitis, intracranial calcification, hydrocephalus, CNS abnormalities, and neonatal death), and
sequelae appearing after the first year of life (chorioretinitis) (Fig 1). Non-specific symptoms
following CT (e.g., anaemia, jaundice, pneumonitis, and diarrhoea) [21] were not considered.
CT was considered possible for infants of previously seronegative mothers who became
infected during pregnancy; the possibility of periconceptional transmission or vertical trans-
mission in mothers deemed seropositive prior to conception was not considered.
Data sources
During the Danish Neonatal Feasibility Study (DNFS), running from June 1992 to August
1996 [12], pregnant women from five counties in Denmark who gave birth to live infants, rep-
resenting one third of all deliveries in the country, were offered screening at delivery for pri-
mary T. gondii infection acquired during pregnancy and for CT. Guthrie cards of newborns
were analysed for T. gondii-specific IgG antibodies (DAKO, Glostrup, Denmark) and during
the last 12 months of the study also for T. gondii-specific IgM antibodies by enzyme immuno-
sorbent assay (EIA). Furthermore, Guthrie cards from T. gondii-infected newborns identified
before September 1, 1995, were also analysed for T. gondii-specific IgM antibodies after being
stored for up to three years. When T. gondii-specific IgG or IgM antibodies were detected on a
Guthrie card, the mother’s first-trimester serum sample (routinely taken for syphilis testing at
weeks 8 to 12 of gestation) was thawed and analysed for T. gondii-specific IgG antibodies. It
was considered evidence of maternal seroconversion if T. gondii-specific IgG or IgM antibod-
ies were detected on the newborns Guthrie card and the mother’s first trimester sample was
negative. First-trimester samples that were negative for IgG by EIA were subsequently analysed
by the Sabin—Feldman dye test. When CT was suspected, confirmatory diagnostic serology
was performed on blood samples from mother and child within 6 weeks after birth [12].
Of 89,873 children sampled during the DNFS, 27 children were diagnosed with CT, corre-
sponding to an apparent incidence of 3.0 per 10,000 live-born children. Follow-up was per-
formed for 26 of the 27 children for late development of chorioretinitis with a maximum
follow-up time of 12 years (4–12 years; median age, 10 years) (https://figshare.com/s/
ca8e1a41aeac216204f1).
Disease burden of congenital toxoplasmosis in Denmark
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The Danish National Neonatal Screening Programme for Congenital Toxoplasmosis
(DNNSP), running from January 1999 to July 2007 [22,23], included > 98% of all newborns in
Denmark. Pregnant women were not screened during the program. Guthrie cards of new-
borns were analysed for T. gondii-specific IgM and IgA antibodies by fluorescence enzyme
immunoassay (FEIA) or time-resolved immunofluorometric assay (TRIFMA). If positive,
Guthrie cards were further analysed by a modified immunosorbent agglutination assay
(ISAGA; bioMe´rieux, France) for T. gondii-specific IgM antibodies. When CT was suspected
(Guthrie card ISAGA IgM-positive), serum samples from both mother and child were ana-
lysed for T. gondii-specific IgG and IgM antibodies by the Vidas system (bioMe´rieux, France),
for IgA antibodies by the Platelia system (PasteurDiagnostics, Paris), for Toxoplasma-specific
antibodies by the Sabin—Feldman’s dye test (in-house, Statens Serum Institut, Copenhagen,
Denmark), and for Toxoplasma-specific IgM by ISAGA (bioMe´rieux, France) [23]. At one
year of age, children diagnosed with CT at birth had a new serum sample analysed for T. gon-
dii-specific IgG antibodies for serological confirmation. Active surveillance of CT in Denmark
was terminated in 2007 [13].
Of the approximately 560,000 children born during the DNNSP, 105 children were diag-
nosed with CT, corresponding to an apparent incidence of 1.9 per 10,000 live-born children.
The 55 children born with CT in the first four years of the DNNSP were followed for three
years for developmental and clinical outcomes [23]; these data were used to estimate sequelae
in the first year of life.
Incidence of CT and related health outcomes
The incidence of CT in newborns appeared stable during the DNNSP, and hence we assumed
it was applicable to the reference year 2014.
To estimate the incidence of CT and the selected associated health outcomes of CT for
2014, we defined a set of parameters (Table 1). We used the number of diagnosed CT cases by
DNNSP and accounted for the sensitivity of the diagnostic approach (largely affected by detec-
tion of T. gondii-specific IgM antibodies on Guthrie card; 70%-80% [12]) to estimate the num-
ber of children born with CT. The proportion of children diagnosed with chorioretinitis,
intracranial calcification, hydrocephalus, and CNS abnormalities were derived from the first
four years of the DNNSP [22,23], and the proportion of children who were asymptomatic in
the first year of life and data on the occurrence of chorioretinitis later in childhood were
derived from a follow-up study of the DNFS.
Initially, we calculated the total number of pregnancies in Denmark in 2014 by summing
the number of live-born children, the number of stillbirths after 22 weeks of gestation, and the
number of registered spontaneous abortions occurring up to 22 weeks of gestation [24].
Fig 1. Health outcome tree for congenital toxoplasmosis (CT), adapted from Havelaar et al. (2007) [18].
https://doi.org/10.1371/journal.pone.0178282.g001
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Assuming that the proportion of women who were seronegative at the beginning of pregnancy
(mean 72.63% ± 0.61 standard deviation [SD]), [25] and the rate of seroconversion of seroneg-
ative pregnant women (0.21%, 95% CI, 0.18–0.25) observed in the DNFS study [12] was appli-
cable to 2014, we estimated the total number of pregnant women who seroconverted during
pregnancy. Next, we estimated the number of pregnancies resulting in foetal loss >22 weeks of
gestation in seroconverting women. Based on the methodology described by Havelaar et al.
(2007) [18] we assumed that the probability of foetal loss in seroconverting mothers is 1.7%
(mean 1.79% ± 0.26 SD) [26], and that foetal losses are generally equally distributed over the
40 weeks of gestation, giving an inclusion of 18 (i.e., 40–22 weeks)/40 of the estimated foetal
losses due to CT in 2014.
To estimate the number of neonatal deaths, and in the absence of reports in Denmark, we
adopted the most likely and maximum values of the probability of CT related neonatal death
from Havelaar et al. (2007) [18] and defined zero as a minimum value for the probability as
observed in DNFS and DNNSP.
All calculations of incidence of CT and of the development of health outcomes were per-
formed using a stochastic model implemented in @risk 6.0 (Palisade Corporation, 2014).
Table 1. Parameters used to estimate the incidence of congenital toxoplasmosis (CT) and selected associated health outcomes.
Notation Description Value/Distribution/
Estimation
Reference
Lb Number of live births in 2014 56,870 Statistics Denmark, accessed on 18
April, 2016
Sb Stillbirths after gestational week 22 in 2014 234 Statistics Denmark, accessed on 18
April, 2016
Sa Number of reported spontaneous abortions occurring up to 22
weeks of gestation
11,928 [24]
Tp Total number of pregnancies Lb + Sb + Sa = 69,104 -
PSeroNeg Proportion of seronegative pregnant women RiskBeta (3925;1479) [25]
PSeroConv Probability of seroconversion during pregnancy RiskBeta (140;64,746) DNFS
Seroconv Number of seroconverting pregnant women Tp* PSeroNeg* PSeroConv -
PToxoAb Probability of fetal loss in seroconverting mothers RiskBeta (48;2,630) [26]
FoetalLoss Number of foetal losses due to CT >22 weeks of gestation Seroconv* PToxoAb*((40–
22)/40)
-
IncCT Annual incidence of CT diagnosed in the first year of life (cases per
10,000)
1.9 DNNSP
Sens Sensitivity of the diagnostic approach 1/RiskUniform (0.7–0.8) DNFS
CasesCT Total cases of postnatal CT (Lb x Inc CT)/Sens -
ProbCS1 Probability of developing sequelae in the first year of life RiskBeta (13;44) DNNSP
ProbCh1 Probability of developing chorioretinitis RiskBeta (8;6) DNNSP
ProbIC Probability of developing intracranial calcifications RiskBeta (11;3) DNNSP
ProbHC Probability of developing hydrocephalus RiskBeta (2;12) DNNSP
ProbCNS Probability of developing CNS abnormalities RiskBeta (2;12) DNNSP
ProbND Probability of neonatal death RiskPert (0;0.007;0.012)* DNFS, DNNSP and [18]
ProbCS2 Probability of being asymptomatic in the first year of life 1-ProbCS1 DNFS
ProbCh2 Probability of developing chorioretinitis later in life (1 to 12 years of
age)
RiskBeta (7;18) DNFS
DNFS: The Danish Neonatal Feasibility Study [12]; DNNSP: The Danish National Neonatal Screening Programme for Congenital Toxoplasmosis [13,22,23]
* Minimum value informed by Danish data (zero neonatal deaths reported in DNFS and DNNSP); most likely and maximum value adapted from Havelaar
et al. (2007) [18]
https://doi.org/10.1371/journal.pone.0178282.t001
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DALYs
To estimate DALYs, we combined incidence of morbidity and mortality estimates with data
on the duration and DWs of the health outcomes, and life expectancy in the population. We
assumed that children with chorioretinitis had, on average, moderately impaired distance
vision [27] and used the updated DW of 0.031 for “moderate vision impairment” reported in
the Global Burden of Disease study (GBD-2013) [15]. The DWs used for the neurological dis-
orders were adopted from Havelaar et al. (2007) [18]. Only foetal loss >22 weeks of gestation
was considered as a death, which consequently resulted in the loss of the full life expectancy
(i.e., 92 years).
To estimate the associated uncertainty, we applied a stochastic model using the DALY Cal-
culator interface developed in R (http://daly.cbra.be/).
Scenario analysis
To estimate the impact of different model specifications and assumptions, we performed sce-
nario analysis (SA) and evaluated the respective changes in the estimate of the disease burden
of CT.
In SA1, the impact of ‘foetal loss’ was excluded from the baseline model, because losing a
foetus may not lead to sequelae in the mother, who might soon become pregnant again. In
SA2, we used different DWs for chorioretinitis, ranging from 0 to 0.2, to assess the impact of
different degrees of visual impairment. The GBD-2013 study defined DWs for distance vision
impairment ranging from 0.003 for mild impairment to 0.187 for severe impairment and
blindness [15]. In SA3, we applied different combinations of non-uniform age weighting and
3% time-discount rate. Application of age weighting relies on the assumption that the life at
different ages is unequally valued; e.g. youngest and oldest age is given less weight. By applying
time discounting, future life-years are assigned less value than those lived today.
Results
Incidence of CT
The annual incidence rates during the DNNSP ranged between 1.2 and 2.9 cases of CT per
10,000 live-born children, with an overall diagnosed incidence rate of 1.9 cases per 10,000 live-
born children for the period 1999–2007 [22,28] (Table 2). We estimated that 14 children (95%
UI, 14–15) were born with CT in 2014. Of these, three children (95% UI, 2–5) were estimated
to be born with CT related sequelae, three children (95% UI, 1–5) were estimated to be asymp-
tomatic in the first year of life but to develop chorioretinitis by the age of 12, and eight children
(95% UI, 6–10) were estimated to be asymptomatic by the age of 12.
Foetal loss
We estimated that 105 women (95% UI, 94–118) acquired a primary T. gondii infection during
pregnancy in 2014, which resulted in an estimate of 0.84 (95% UI 0.6–1.0) CT-related foetal
losses.
Incidence of clinical health outcomes of CT
The estimated incidence of each health outcome of CT in 2014 is presented in Table 3. Among
those with sequelae of CT in the first year of life, the most frequent outcomes were estimated
to be intracranial calcification (3 cases; 95% UI, 1–4), and chorioretinitis (2 cases; 95% UI,
1–3). Hydrocephalus and CNS abnormalities were estimated to be less frequent (0.4 cases; 95%
UI, 0–1). We estimated 0.02 neonatal deaths (95% UI, 0–0.03), and that three cases (95% UI,
Disease burden of congenital toxoplasmosis in Denmark
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1–5) of chorioretinitis would have occurred among the children born with asymptomatic CT
in 2014 at some point between 1 and 12 years of age.
DALYs
The estimated disease burden of CT in Denmark in 2014 was 123 DALYs (95% UI, 100–148)
(Table 3), with a total of 80 YLLs (95% UI, 66–96) and 42 YLDs (95% UI, 27–62). Foetal loss
resulted in 78 DALYs (95% UI, 64–94), representing more than 50% of the total disease bur-
den, and neonatal death resulted in 2 DALYs (95% UI, 1–3). Despite the low incidence,
Table 2. Incidence of congenital toxoplasmosis (CT) in Denmark from January 1, 1999, to July 31, 2007; cases per 10,000 live-born children.
Year 1999 2000 2001 2002 2003 2004 2005 2006 2007*** 1999–2007***
Live-births in Denmark* (n) 66,220 67,084 65,458 64,075 64,599 64,609 64,282 67,131 36,689 560.147
Diagnosed with CT** (n) 11 13 19 12 13 8 9 14 6 105
Incidence per 10,000 1.7 1.9 2.9 1.9 2.0 1.2 1.4 2.1 1.6 1.9
* Statistics Denmark, accessed on 18 April, 2016 (http://www.danmarksstatistik.dk/en)
** The Danish National Neonatal Screening Programme for Congenital Toxoplasmosis (DNNSP).
*** DNNSP was terminated on July 31, 2007.
https://doi.org/10.1371/journal.pone.0178282.t002
Table 3. Estimated incidence and disease burden of congenital toxoplasmosis (CT) in Denmark, 2014.
Reported
cases1 1999–
2002
Estimated cases Duration
years2
Disability weight
(Mean and 95% UI)
Total DALYs3
(Median and 95%
UI)Cases per 1,000 livebirths in 2014 (Median
and 95% UI)
Total cases in 2014
(Median and 95%
UI)
Foetal loss
 22 weeks of gestation
- - 0.84 (0.6–1) 92 1 78 (64–94)
Symptomatic in the first year of life
Chorioretinitis 7 0.03 (0.01–0.06) 2 (1–3) 81 0.031 (0.019–
0.049)
5 (3–8)
Intracranial calcification 10 0.04 0.02–0.07) 3 (1–4) 81 0.01* 2 (1–3)
Hydrocephalus 1 0.01 (0.001–0.02) 0.40 (0–1) 81 0.36 (0.16–0.56) 13 (4–29)
CNS abnormalities 1 0.01 (0.001–0.02) 0.40 (0–1) 81 0.36* 14 (5–27)
Neonatal death4 0 0.0004 (0.0001–0.001) 0.02 (0–0.03) 92 1 2 (1–3)
Asymptomatic in the first year of life
Chorioretinitis later in life
(Follow up to 12 years)5
6 0.05 (0.02–0.1) 3 (1–5) 69 0.031 (0.019–
0.049)
7 (4–11)
Total - - - - - 123 (100–148)
DALYs, disability-adjusted life years; UI, uncertainty interval.
1Number of cases reported from the initial four years (1999–2002) of the Danish National Neonatal Screening Programme for CT (DNNSP[22,23]), which
included >98% of newborns
2Duration of all health outcomes is life-long. We used the Danish life expectancy table (www.danmarksstatistik.dk/en) to estimate YLDs and the frontier
national life expectancy projected for the year 2050 by the World Population Prospects 2012 (UN Population Division, 2013) [20] to estimate YLLs.
3Calculated as median incidence x duration x disability weight
4Minimum data from Denmark (zero neonatal deaths reported in initial four years [1999–2002] of DNNSP [23]); most likely and high value adapted from
Havelaar et al. (2007) [18], giving an interval of 0.7% (0–1.2)
5Chorioretinitis later in life (at the age of 4–12 years) based on follow-up observations of The Danish Neonatal Feasibility Study (DNFS).
* No uncertainty interval available.
https://doi.org/10.1371/journal.pone.0178282.t003
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hydrocephalus and CNS abnormalities were estimated to cause 13 DALYs (95% UI, 4–29) and
14 DALYs (95% UI, 5–27), respectively; the remaining health outcomes caused a lower
burden.
Scenario analyses
Excluding the impact of foetal loss (SA1) reduced the overall burden of disease to 44 DALYs
(95% UI, 28–64) or 4.89 DALYs per case (S1 Table). Assuming that all cases of chorioretinitis
would be mild (i.e., DW = 0; SA2), the estimated disease burden per case was 1.1 times lower
than the estimate of the baseline model (S1 Table). On the contrary, assuming that all cases of
chorioretinitis would be severe (i.e., DW = 0.2; SA2), the estimated disease burden per case
was 1.5 times higher than the estimate of the baseline model (S1 Table).
The analyses with different combinations of age weighting and time discounting (SA3)
showed that if life is valued unequally at different stages of life (applying age weighting), the
estimate of disease burden would be highest (14 DALYs per case) (S1 Table). Conversely, not
including age weighting but assuming that future life years are assigned less value than those
lived today (applying time discounting) yielded a lower estimate of disease burden (five
DALYs per case) (S1 Table).
Under-ascertainment of CT
Since the DNNSP was terminated in July 2007, between zero and five infants were registered
with CT in Denmark annually (2008–2014) (Table 4). Comparing our estimated incidence
with the number of registered CT cases suggests that for each reported CT case, at least five
other CT cases could be expected to have occurred (95% UI, 2–7). Furthermore, our estimates
show that even symptomatic CT cases could have been missed.
Discussion
We estimated that 14 children were born with CT in 2014, which corresponded to a total dis-
ease burden of 123 DALYs. Our results are in agreement but slightly higher than the findings
by Torgerson and Mastroiacovo (2013) who estimated 13 CT (95% CI, 10–16) cases per year
causing 82 DALYs (95% CI, 44–137) for Denmark [27]. In our model, most of the years of life
lost were due to foetal losses and to the occurrence of relatively severe and life-long sequelae in
children since birth. The clinical manifestations resulting in the highest number of healthy life
years lost were estimated to be hydrocephalus and CNS abnormalities.
The main strength of this study was that regional and nationwide data were available for
estimating the disease burden of CT at the national level. Because the DNNSP was a national
surveillance programme including more than 98% of all newborns over a period of 8.5 years,
we assumed that our estimates of the incidence of CT in Denmark have low uncertainty,
which derives mostly from the sensitivity of the diagnostic approach (in particular detection of
IgM antibodies on Guthrie cards by EIA). In the DNNSP, the diagnosis of CT relied on a two-
step detection algorithm involving detection of T. gondii-specific IgM and IgA antibodies on
Guthrie cards and confirmatory serology on mother and child. The use of more diagnostic
tests and confirmational testing may increase the sensitivity. These estimates rely on the
assumption that the incidence of CT was relatively stable after the termination of the survey
period and until 2014. Likewise, we assumed that the seroprevalence of T. gondii was stable in
the same period. Data from 1990, when the overall prevalence of T. gondii-specific IgG anti-
bodies in pregnant women in Denmark was 27% [25] and data from 2014 showing that 23% of
4,571 Danish blood donors (men and women) aged 18–67 years had T. gondii-specific IgG
antibodies (unpublished data) support this assumption. Even though the latter data are not
Disease burden of congenital toxoplasmosis in Denmark
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directly comparable because they include a wider age range (and men), they suggest a stability
of the seroprevalence in the population.
The major limitations affecting our estimates were the data gaps faced when estimating foe-
tal loss, neonatal death, and seroconversions, and not including all possible health outcomes.
For example, we used French data to estimate foetal loss. In France, an active prenatal screen-
ing program for CT for pregnant women has been established, which might result in a higher
number of voluntary or medical terminations of pregnancy due to CT compared with other
countries, including Denmark. In Denmark, voluntary and medical termination of pregnancy
due to CT is less likely as most CT cases are not detected during pregnancy. In addition, we
were not able to account for seroconversion before weeks 8 to 12 of gestation or seroconver-
sions of the pregnant women where no transplacental transmission of T. gondii and/or IgG to
the child happened. Moreover, because children from the DNFS were only followed until
being 12 years of age, we were not able to account for possible sequelae later in life; thus, our
estimates might under-estimate the true impact of the disease burden of CT. Additionally, we
estimated that some children had more than one sequela, which could potentially lead to a
higher disease burden in these cases. We were at this stage unable to account for co-morbidity,
which potentially means we under-estimated the overall burden of disease.
The estimated disease burden of CT in Denmark in 2014 amounted to 123 DALYs. This
shows that the annual disease burden of CT was substantially lower than the annual disease
burden caused by salmonellosis (379 DALYs) and campylobacteriosis (1.586 DALYs) in Den-
mark [29]. It is however important to highlight that our estimates reflect the burden of CT
only, and that the health impact of acquired toxoplasmosis (i.e., post-natal infection) is still
unknown and needs to be assessed. Moreover, while the proportion of the disease burden
attributable to foodborne transmission varies (61% for CT in low-child-mortality European
countries compared with 76% for the other two diseases [1]), the relative contribution of dif-
ferent foods and the effect of different cooking and eating habits remain unknown. Our results
highlight the need for further studies to identify the most important sources of T. gondii infec-
tion in order to identify effective pathogen-specific interventions for reducing the burden of
disease at a national level.
The estimated disease burden of CT in Denmark is lower than that estimated in The Neth-
erlands. The most recent Dutch study estimated that CT caused 2,251 DALYs annually
between 2007 and 2011 [7], resulting in 13.4 DALYs per 100,000 inhabitants, whereas our
results show a disease burden of 2.2 DALYs per 100,000 inhabitants. This difference can
mostly be explained by the lower incidence of CT in Denmark. In Denmark, the apparent CT
Table 4. Number of estimated (1) and registered (2) cases of congenital toxoplasmosis (CT) in Denmark in the period of 2008–2014.
Year 2008 2009 2010 2011 2012 2013 2014
Live-births in DK* 65,038 62,818 63,411 58,998 57,916 55,873 56,870
1. Total estimated no. of CT cases 16 16 16 15 15 14 14
No. of cases with sequelae in the first year of life 4 4 4 3 3 3 3
No. of cases with no sequelae in the first year of life but who will have developed
chorioretinitis by the age of 12
3 3 3 3 3 3 3
No. of cases who will not have developed sequelae by the age of 12 9 9 9 8 8 8 8
2. No. of registered cases of CT** 5*** 1 3 0 1 1 0
* Statistics Denmark, accessed on 1 June 2016 (http://www.danmarksstatistik.dk/en/)
** The Danish National Registry of Patients, accessed on 23 June 2016.
*** One of these cases was registered only in 2009.
https://doi.org/10.1371/journal.pone.0178282.t004
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incidence of 1.9 per 10,000 live-born children was captured through DNNSP [13], with high
coverage over 8.5 years. When comparing the incidence estimates obtained using comparable
methods, the incidence of CT in Denmark was almost 11 times lower than in The Netherlands
[30], two times lower than in Poland [31], and slightly higher than in Ireland [30]. Likewise,
the incidence of CT in countries with low child mortality status, including EU, was estimated
by WHO—FERG to be five cases per 10,000 live births, which is three times higher than the
incidence observed in Denmark [32].
Differences in the DALY estimates may also reflect differences in input parameters. In par-
ticular, we used the recently updated DW for “moderate impairment” (0.031) for chorioretini-
tis [15], whereas a higher DW (0.08) was used by Havelaar et al. (2007) [18] and Kortbeek et al.
(2009) [30]. Applying a DW of 0.08 for chorioretinitis in our model, the estimate increased to
140 (95% UI, 117–167) DALYs per year. Other differences in input parameters were related to
life expectancy and incidence of sequelae assumed in the two models.
Since the termination of DNNSP in 2007, zero to five children have been diagnosed with
CT annually. Our model estimated that 14 children were born with CT in 2014, and that three
children had clinical sequelae of CT in the first year of life; however, no CT cases were regis-
tered in 2014; hence, even symptomatic CT cases are missed. These data suggest that CT is cur-
rently under-diagnosed or under-reported and that public health surveillance data provide an
incomplete picture of the impact of the disease in the country.
Conclusions
We show that the estimated disease burden and public health impact of CT in Denmark are
lower than what has been estimated in other European countries, highlighting the need for
country-specific studies. Nevertheless, our study indicates that CT is under-diagnosed or
under-reported in Denmark. CT may be a serious and life-long disease, and knowledge on its
public health impact is critical to guiding public health policy at the national level.
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